Champions Oncology Inc (CSBR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Champions Oncology Inc (CSBR) has a cash flow conversion efficiency ratio of -0.306x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.34 Million) by net assets ($4.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Champions Oncology Inc market capitalisation for the company's overall valuation and market capitalisation.
Champions Oncology Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Champions Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Champions Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Champions Oncology Inc ranked by their cash flow conversion efficiency. Explore CSBR cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Polygon-L
TA:POLY
|
0.059x |
|
DMCC SPECIALITY CHEMICALS LIMITED
NSE:DMCC
|
0.070x |
|
Guizhou Zhongyida Co Ltd
SHG:900906
|
0.195x |
|
Hwa Sung Ind
KO:002460
|
0.010x |
|
Deneb Investments Ltd
JSE:DNB
|
0.147x |
|
Sheh Fung Screws Co Ltd
TWO:2065
|
0.021x |
|
SEAL Incorporated Bhd
KLSE:4286
|
-0.008x |
|
Coffee Day Enterprises Limited
NSE:COFFEEDAY
|
0.025x |
Annual Cash Flow Conversion Efficiency for Champions Oncology Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Champions Oncology Inc from 1996 to 2025. View current stock price of Champions Oncology Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-04-30 | $3.77 Million | $7.39 Million | 1.958x | -39.28% |
| 2024-04-30 | $-1.90 Million | $-6.14 Million | 3.225x | +278.02% |
| 2023-04-30 | $4.64 Million | $3.96 Million | 0.853x | +19.44% |
| 2022-04-30 | $9.10 Million | $6.50 Million | 0.714x | +415.62% |
| 2021-04-30 | $7.43 Million | $-1.68 Million | -0.226x | -139.72% |
| 2020-04-30 | $5.10 Million | $2.90 Million | 0.570x | -31.52% |
| 2019-04-30 | $2.24 Million | $1.86 Million | 0.832x | -98.30% |
| 2018-04-30 | $-25.00K | $-1.23 Million | 49.040x | +790.70% |
| 2017-04-30 | $400.00K | $-2.84 Million | -7.100x | +73.81% |
| 2016-04-30 | $238.00K | $-6.45 Million | -27.109x | -2168.67% |
| 2015-04-30 | $8.06 Million | $-9.63 Million | -1.195x | -11.28% |
| 2014-04-30 | $3.20 Million | $-3.43 Million | -1.074x | -91.58% |
| 2013-04-30 | $7.60 Million | $-4.26 Million | -0.560x | -156.60% |
| 2012-04-30 | $-5.28 Million | $-5.23 Million | 0.990x | +134.85% |
| 2011-04-30 | $19.00K | $-54.00K | -2.842x | -113.43% |
| 2010-04-30 | $1.58 Million | $-2.10 Million | -1.332x | -187.32% |
| 2009-04-30 | $1.92 Million | $-888.00K | -0.463x | -312.75% |
| 2008-04-30 | $3.64 Million | $792.40K | 0.218x | -27.53% |
| 2007-04-30 | $-261.06K | $-78.47K | 0.301x | +114.48% |
| 2006-04-30 | $-670.51K | $-93.97K | 0.140x | +44.39% |
| 2005-04-30 | $-366.80K | $-35.60K | 0.097x | -87.51% |
| 2004-04-30 | $-92.70K | $-72.05K | 0.777x | -34.29% |
| 2003-04-30 | $-209.75K | $-248.12K | 1.183x | -81.89% |
| 2002-04-30 | $-5.00K | $-32.68K | 6.530x | +581.82% |
| 2001-04-30 | $151.06K | $144.68K | 0.958x | +4754.15% |
| 2000-04-30 | $891.69K | $-18.35K | -0.021x | -116.65% |
| 1999-04-30 | $890.00K | $110.00K | 0.124x | -72.34% |
| 1998-04-30 | $940.00K | $420.00K | 0.447x | +164.02% |
| 1997-04-30 | $650.00K | $110.00K | 0.169x | +342.56% |
| 1996-04-30 | $430.00K | $-30.00K | -0.070x | -- |
About Champions Oncology Inc
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform … Read more